297 related articles for article (PubMed ID: 32268367)
1. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
Stiekema LCA; Prange KHM; Hoogeveen RM; Verweij SL; Kroon J; Schnitzler JG; Dzobo KE; Cupido AJ; Tsimikas S; Stroes ESG; de Winther MPJ; Bahjat M
Eur Heart J; 2020 Jun; 41(24):2262-2271. PubMed ID: 32268367
[TBL] [Abstract][Full Text] [Related]
2. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
Viney NJ; van Capelleveen JC; Geary RS; Xia S; Tami JA; Yu RZ; Marcovina SM; Hughes SG; Graham MJ; Crooke RM; Crooke ST; Witztum JL; Stroes ES; Tsimikas S
Lancet; 2016 Nov; 388(10057):2239-2253. PubMed ID: 27665230
[TBL] [Abstract][Full Text] [Related]
4. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
[TBL] [Abstract][Full Text] [Related]
6. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
Reiner Ž
Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
[TBL] [Abstract][Full Text] [Related]
7. Antisense Oligonucleotides Targeting Lipoprotein(a).
Langsted A; Nordestgaard BG
Curr Atheroscler Rep; 2019 May; 21(8):30. PubMed ID: 31111240
[TBL] [Abstract][Full Text] [Related]
8. Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A; Watts GF; Schneider WJ; Tsimikas S; Kovanen PT
J Intern Med; 2020 Jan; 287(1):2-18. PubMed ID: 31858669
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of proprotein convertase subtilisin/kexin-9 monoclonal antibody treatment on plasma lipoprotein(a) concentrations in patients with elevated lipoprotein(a) attending a clinic.
Chakraborty A; Pang J; Chan DC; Barnett W; Woodward AM; Vorster M; Watts GF
Clin Cardiol; 2021 Jun; 44(6):805-813. PubMed ID: 33955565
[TBL] [Abstract][Full Text] [Related]
10. The Role of Antisense Therapies Targeting Lipoprotein(a).
Plakogiannis R; Sorbera M; Fischetti B; Chen M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e5-e11. PubMed ID: 34232223
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) Particle Production as a Determinant of Plasma Lipoprotein(a) Concentration Across Varying Apolipoprotein(a) Isoform Sizes and Background Cholesterol-Lowering Therapy.
Chan DC; Watts GF; Coll B; Wasserman SM; Marcovina SM; Barrett PHR
J Am Heart Assoc; 2019 Apr; 8(7):e011781. PubMed ID: 30897995
[TBL] [Abstract][Full Text] [Related]
12. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
13. The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors.
Blanchard V; Chemello K; Hollstein T; Hong-Fong CC; Schumann F; Grenkowitz T; Nativel B; Coassin S; Croyal M; Kassner U; Lamina C; Steinhagen-Thiessen E; Lambert G
Cardiovasc Res; 2022 Jul; 118(9):2103-2111. PubMed ID: 34314498
[TBL] [Abstract][Full Text] [Related]
14. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment.
Stiekema LCA; Stroes ESG; Verweij SL; Kassahun H; Chen L; Wasserman SM; Sabatine MS; Mani V; Fayad ZA
Eur Heart J; 2019 Sep; 40(33):2775-2781. PubMed ID: 30561610
[TBL] [Abstract][Full Text] [Related]
15. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1.
Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP
Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484
[TBL] [Abstract][Full Text] [Related]
16. Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach.
Greco MF; Sirtori CR; Corsini A; Ezhov M; Sampietro T; Ruscica M
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32635396
[TBL] [Abstract][Full Text] [Related]
17. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
18. The roles of apo(a) size, phenotype, and dominance pattern in PCSK9-inhibition-induced reduction in Lp(a) with alirocumab.
Enkhmaa B; Anuurad E; Zhang W; Yue K; Li CS; Berglund L
J Lipid Res; 2017 Oct; 58(10):2008-2016. PubMed ID: 28798072
[TBL] [Abstract][Full Text] [Related]
19. Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.
Watts GF; Chan DC; Somaratne R; Wasserman SM; Scott R; Marcovina SM; Barrett PHR
Eur Heart J; 2018 Jul; 39(27):2577-2585. PubMed ID: 29566128
[TBL] [Abstract][Full Text] [Related]
20. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
